NHS Galleri trial misses its main goal on late-stage cancer reduction
Results from the UK's largest randomized trial of the Galleri multi-cancer blood test showed no statistically significant reduction in late-stage cancers (stages 3–4) when added to standard screening; while a secondary look at stage-4 cancers suggested a 14% reduction, mortality outcomes are still pending.